Martínez-García, MariaÁlvarez-Linera, JuanCarrato, CristinaLey, L.Luque, RaquelMaldonado, X.Martínez-Aguillo, M.Navarro, L.M.Vaz-Salgado, M.A.Gil-Gil, Miguel J.2018-05-042018-05-042017Martínez-Garcia M, Álvarez-Linera J, Carrato C, Ley L, Luque R, Maldonado X. et al. SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017). Clin Transl Oncol. 2018 Jan;20(1):22-28. DOI: 10.1007/s12094-017-1763-61699-048Xhttp://hdl.handle.net/10230/34552Glioblastoma (GB) is the most common brain malignancy and accounts for over 50% of all high-grade gliomas. Radiotherapy (RT) with concomitant and adjuvant temozolomide (TMZ) chemotherapy is the current standard of care for patients with newly diagnosed GB up to age 70. Recently, a new standard of care has been adopted for elderly patients (≥ 65 years) based on short course of RT and TMZ. Several clinically relevant molecular markers that assist in diagnosis and prognosis have recently been identified. The treatment for recurrent GB is not well defined, and decision-making is usually based on prior strategies as well as several clinical and radiological factors. The presence of neurologic deficits and seizures can significantly impact quality of life.application/pdfengThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.Glioblastoma multiformeinfo:eu-repo/semantics/articlehttp://dx.doi.org/10.1007/s12094-017-1763-6DiagnosisGlioblastomaGuidelinesTreatmentinfo:eu-repo/semantics/openAccess